Texas Transplant/St David's South Austin
Welcome,         Profile    Billing    Logout  
 1 Trial 
5 Trials

   

 
Trial + Data / EventsStatusPhNRegionInterventionsSponsorConditionsPrimary complStudy compl
Ramakrishnan, Aravind
ACCESS, NCT04904588: HLA-Mismatched Unrelated Donor Hematopoietic Cell Transplantation With Post-Transplantation Cyclophosphamide

Recruiting
2
300
US
Busulfan, Busulfex®, Fludarabine, Fludara®, Total-body irradiation, TBI, Cyclophosphamide, Cytoxan®, Melphalan, PBSC Hematopoietic Stem Cell Transplantation (HSCT), PBSC HSCT, PBSC HCT, PBSC Transplantation, Bone Marrow Hematopoietic Stem Cell Transplantation, BM HSCT, BM HCT, Bone Marrow Transplantation, Post-transplant Cyclophosphamide, Mesna, Mesnex®, Tacrolimus, Mycophenolate Mofetil, MMF, Cellcept®, Patient-Reported Outcomes
Center for International Blood and Marrow Transplant Research, National Marrow Donor Program
Acute Lymphoblastic Leukemia, Acute Myelogenous Leukemia, Mixed Phenotype Acute Leukemia, Acute Leukemia, Myelodysplastic Syndromes, Chronic Myelogenous Leukemia, Chronic Lymphocytic Leukemia, Lymphoma
07/24
07/24
CYTB323A12101, NCT03960840: Phase I/II Study of Rapcabtagene Autoleucel in CLL, 3L+ DLBCL, r/r ALL and 1L HR LBCL

Recruiting
1/2
225
Europe, Japan, US, RoW
Rapcabtagene autoleucel single agent, Ibrutinib
Novartis Pharmaceuticals
Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma, Diffuse Large B-cell Lymphoma, Acute Lymphoblastic Leukemia, Large B-cell Lymphoma
06/27
05/28
NCT05627323: CAR T Cells in Patients With MMP2+ Recurrent or Progressive Glioblastoma

Active, not recruiting
1
42
US
CHM-1101 CAR-T cells, Chlorotoxin (EQ)-CD28-CD3zeta-CD19t-expressing CAR T-lymphocytes (via ICT/ICV dual delivery), Chlorotoxin-CD28-CD3z-CD19t-expressing CAR T-cells
Chimeric Therapeutics
Glioblastoma Multiforme of Brain
10/25
01/41
SGR-2921-101, NCT05961839: Study of SGR-2921 in Relapsed/Refractory Acute Myeloid Leukemia or Myelodysplastic Syndrome

Recruiting
1
50
US
SGR-2921
Schrödinger, Inc.
Acute Myeloid Leukemia, High-Risk and Very High-Risk Myelodysplastic Syndromes
12/25
12/25
APOLLO, NCT05798897: Safety and Preliminary Efficacy of MT-601 in Patients With Relapsed/Refractory Lymphoma

Recruiting
1
79
US
MT-601
Marker Therapeutics, Inc.
Non-Hodgkin Lymphoma, Adult, Non-Hodgkin Lymphoma, Refractory, Non-Hodgkin Lymphoma, Relapsed, Non Hodgkin Lymphoma, Hodgkin Lymphoma, Hodgkin Lymphoma, Adult, Hodgkin's Lymphoma, Relapsed, Adult
02/28
02/28

Download Options